How Novo Nordisk’s Share‑Buyback, AWS AI R&D, and Germany Wegovy Launch Drive Shareholder Value
Novo Nordisk’s dual‑track plan—share‑buyback, AWS AI R&D and Wegovy’s German launch—boosts EPS, cuts drug‑development costs and captures high‑margin obesity therapy demand.
4 minutes to read